Literature DB >> 28695658

Fecal Microbial Transplantation in Inflammatory Bowel Disease: A Movement Too Big to Be Ignored.

M Laffin1,2, K L Madsen2,3.   

Abstract

The development of new therapies for inflammatory bowel disease is plagued by high costs, potential side effects, and variable levels of effectiveness. Fecal microbial transplant in inflammatory bowel diseases can offer an alternative to traditionally developed pharmacologic therapies and has demonstrated the ability to induce disease remission in randomized control trials. However, questions remain about the ultimate role of this therapy in disease management, including long term safety, and the optimal composition of transplanted stool.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2017        PMID: 28695658     DOI: 10.1002/cpt.747

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  The success of fecal microbial transplantation in Clostridium difficile infection correlates with bacteriophage relative abundance in the donor: a retrospective cohort study.

Authors:  Heekuk Park; Michael R Laffin; Juan Jovel; Braden Millan; Jae E Hyun; Naomi Hotte; Dina Kao; Karen L Madsen
Journal:  Gut Microbes       Date:  2019-03-13

2.  A systems pharmacology model for inflammatory bowel disease.

Authors:  Violeta Balbas-Martinez; Leire Ruiz-Cerdá; Itziar Irurzun-Arana; Ignacio González-García; An Vermeulen; José David Gómez-Mantilla; Iñaki F Trocóniz
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

3.  Improvement of Good's syndrome by fecal microbiota transplantation: the first case report.

Authors:  Sabreen Abdul Rahman Jagessar; Chuyan Long; Bota Cui; Faming Zhang
Journal:  J Int Med Res       Date:  2019-06-20       Impact factor: 1.671

Review 4.  Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy.

Authors:  Romain Daillère; Lisa Derosa; Mélodie Bonvalet; Nicola Segata; Bertrand Routy; Manuela Gariboldi; Eva Budinská; I Jolanda M De Vries; Alessio Gordon Naccarati; Valérie Zitvogel; Carlos Caldas; Lars Engstrand; Sibylle Loilbl; Jacques Fieschi; Lucie Heinzerling; Guido Kroemer; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2020-06-03       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.